Published • loading... • Updated
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
- FibroBiologics started dosing patients in a Phase 1/2 clinical trial of CYWC628 to treat diabetic foot ulcers .
- The company completed manufacturing three batches of CYWC628 drug product following FDA's Current Good Manufacturing Practices .
- FibroBiologics enhanced its financial position via a $9 million private placement, including $3 million upfront and up to $6 million from warrant exercises.
Insights by Ground AI
23 Articles
23 Articles
Denton Record-Chronicle+22 Reposted by 22 other sources
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
First patients dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers
·Denton, United States
Read Full ArticleCoverage Details
Total News Sources23
Leaning Left2Leaning Right3Center13Last UpdatedBias Distribution72% Center
Bias Distribution
- 72% of the sources are Center
72% Center
11%
C 72%
R 17%
Factuality
To view factuality data please Upgrade to Premium
